Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • Data Privacy
  • Français
  • my CNW 
    • Login
    • Register
  • Client Login 
    • Online Member Centre
    • Next Gen Communications Cloud
    • Cision Communications Cloud®
  • Sign Up
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
Advanced Search
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Canadian Federal Government
      • Canadian Municipal Government
      • Canadian Provincial Government
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

  • Advanced Search
  • Overview
  • Cision Communications Cloud®
  • Monitoring
  • Distribution
  • Multimedia
  • Guaranteed Paid Placement
  • AI Tools
  • IR
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media
  • Worldwide Offices
  • Hamburger menu
  • Cision Canada
  • Send a Release
  • FR
    • Phone

    • 877-269-7890 from 8 AM - 10 PM ET

    • ALL CONTACT INFO
    • Contact Cision

      877-269-7890
      from 8 AM - 10 PM ET

  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR
  • Overview
  • Cision Communications Cloud®
  • Monitoring
  • Distribution
  • Multimedia
  • Guaranteed Paid Placement
  • AI Tools
  • IR
  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media
  • Worldwide Offices
  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR

Canadian Solution to Medical-Isotope Crisis Demonstrates that Cities Could Produce their own Medical Isotopes


News provided by

TRIUMF (Canada's National Laboratory of Particle and Nuclear Physics)

Jun 09, 2013, 15:00 ET

Share this article

Share toX

Share this article

Share toX

VANCOUVER, June 9, 2013 /CNW/ - With Canadian-developed tools and technology, a national team led by TRIUMF has reached a crucial milestone at the BC Cancer Agency in developing and deploying alternatives for supplying key medical isotopes. The team used a medical cyclotron that was designed and manufactured by Advanced Cyclotron Systems, Inc. (ACSI) of Richmond, BC, and successfully achieved large-scale production of technetium-99m (Tc-99m), sufficient for a metropolitan area.

The team announced the successful ramp-up of its technology to regularly produce enough of the critical Tc-99m isotope to supply an urban area the size of Vancouver.  This achievement eliminates the need for nuclear reactors to produce isotopes, especially those that use weapons-grade uranium, which has been the traditional approach.

Paul Schaffer, head of TRIUMF's Nuclear Medicine Division and principal investigator for the project, said, "This achievement is a crucial step on the road to meeting Canada's isotope needs after the NRU ceases production in 2016.  This effort required teamwork and dedication from many people."  In addition to TRIUMF, Canada's national laboratory for particle and nuclear physics, the team includes experts at the BC Cancer Agency, the Centre for Probe Development and Commercialization (CPDC), and Lawson Health Research Institute.

Each year, tens of millions of medical procedures are conducted around the world with Tc-99m, an isotope used in radiopharmaceuticals for imaging disease in the heart, bones, and elsewhere in the body.  A small number of ageing reactors account for most of the global capacity for isotope production; one of them is the AECL National Research Universal (NRU) reactor in Chalk River, Ontario.  In the past few years, these reactors have suffered maintenance and repair outages, threatening the global supply of medical isotopes. 

"Today's milestone demonstrates the positive, tangible results being achieved by our government's investments in jobs and science," said Wai Young Member of Parliament for Vancouver South, on behalf of Canada's Natural Resources Minister, Joe Oliver. "Our contributions are supporting jobs and helping advance new technologies for the production of the key medical isotope, Tc-99m."

"The BC Cancer Agency is very proud of our team's time, effort, and use of specialized research expertise to make it possible to produce large quantities of Tc-99m with medical-cyclotron technology," said Dr. Max Coppes, president of the BC Cancer Agency. "This work is a great example of the innovation that can be created through multidisciplinary research and partnerships."

Richard Eppich, CEO and President of ACSI, noted, "We are proud of the TRIUMF team and of our equipment; this demonstration validates the overall approach that Canada has been championing—that modern, high-power cyclotrons can produce all of the essential medical isotopes needed in the best hospitals and clinics."

"The approach taken by our consortium has established the feasibility of producing appreciable quantities of Tc-99m on Canada's existing cyclotron network.  These same machines are also producing additional isotopes used in a growing number of alternative imaging procedures. The net effect is that Canada will remain on the forefront of medical-isotope technology for the foreseeable future," said John Valliant, Scientific Director and CEO of the CPDC in Hamilton.

In February 2012, the TRIUMF-led team demonstrated that the production of Tc-99m was possible on existing medical cyclotrons based in BC and Ontario.  After a year of scaling up performance and making engineering improvements to target fabrication, control, and purification procedures, the team has achieved its next milestone: the production of enough Tc-99m in a six-hour overnight shift at the BC Cancer Agency Vancouver Centre to supply the demands of a metropolitan area (roughly equivalent to 10 Curies).  The next milestones for TRIUMF and its partners include engineering optimization and regulatory approval.

Michael Kovacs, imaging scientist at Lawson Health Research Institute said, "This milestone is key to our plans to deploy this technology to the existing medical cyclotron facilities in Canada, and hundreds more worldwide.  The diversification of the Tc-99m supply chain with robust and cost-effective cyclotron-based technology will reduce the dependence on the conventional, reactor-derived supply."

Commenting on the path forward, TRIUMF's director Nigel Lockyer said, "Having cleared this technical hurdle, we are well on our way to assembling the right team to make a competitive proposal to join the BC supply chain for medical isotopes such as technetium-99m.  I look forward to working with existing and new partners, including ACSI, in making this possible."

The recent breakthroughs have been supported by the Isotope Technology Acceleration Program (ITAP) of Natural Resources Canada.  Initial research on cyclotron production of Tc-99m was supported by Canada's National Sciences and Engineering Research Council and the Canadian Institutes for Health Research through a research grant awarded to the University of British Columbia to support a team led by Dr. François Bénard and Dr. Thomas J. Ruth, from the BC Cancer Agency and TRIUMF, respectively.

For more information and media resources, please see http://www.triumf.ca/nrcan-isotopes.

About TRIUMF
TRIUMF is Canada's national laboratory for particle and nuclear physics. Together with its partner AAPS, Inc., TRIUMF also seeks to commercialize its technologies for the benefit of all Canadians. Located on the south campus of the University of British Columbia, TRIUMF receives operating support from the Government of Canada through a contribution agreement via National Research Council Canada; the Government of British Columbia provides capital for new buildings.  TRIUMF is owned and operated as a joint venture by a consortium of the following Canadian universities: University of Alberta, University of British Columbia, University of Calgary, Carleton University, University of Guelph, University of Manitoba, McGill University, McMaster University, Université de Montréal, University of Northern British Columbia, Queen's University, University of Regina, Saint Mary's University, Simon Fraser University, University of Toronto, University of Victoria, University of Winnipeg, and York University. For more information, please visit us at http://www.triumf.ca.

About ACSI
In 2003, Ebco Industries—using technology licensed from world-renowned subatomic-physics research centre, TRIUMF—founded ACSI with a goal to revolutionize cyclotron design.  Since then, ACSI has specialized in producing advanced cyclotrons that can meet the world's growing isotope needs.  As part of the Government of Canada's Isotope Technology Acceleration Program (ITAP), ACSI is a member of a consortium funded alongside the TRIUMF team to develop viable alternatives to nuclear reactor-produced medical isotopes. For more information, please visit us at http://www.advancedcyclotron.com.

About the BC Cancer Agency
The BC Cancer Agency, an agency of the Provincial Health Services Authority, is committed to reducing the incidence of cancer, reducing the mortality from cancer, and improving the quality of life of those living with cancer. It provides a comprehensive cancer control program for the people of British Columbia by working with community partners to deliver a range of oncology services, including prevention, early detection, diagnosis and treatment, research, education, supportive care, rehabilitation and palliative care. The BC Cancer Foundation raises funds to support research and enhancements to patient care at the BC Cancer Agency.

About the Centre for Probe Development and Commercialization
The Centre for Probe Development and Commercialization (CPDC) discovers, develops and distributes molecular imaging probes for the early diagnosis of diseases and to assess the effectiveness of treatments. An important part of Ontario's health system, CPDC provides a reliable, daily supply of imaging probes to hospitals across the province. CPDC also works collaboratively with industry and academic partners, offering the research, manufacturing and regulatory expertise needed to move innovative probe technology and new therapeutic drugs from R&D labs to clinical use. CPDC, located on the McMaster University Campus, is a Centre of Excellence for Commercialization and Research, part of the Networks of Centres of Excellence Program. It is supported by the Ontario Institute for Cancer Research, GE Healthcare, Cancer Care Ontario, and McMaster University.

About Lawson Health Research Institute
Lawson Health Research Institute, located in London, Ontario, is one of Canada's largest and most respected hospital-based research institutes. As the research arm of London Health Sciences Centre and St. Joseph's Health Care, London, and working in partnership with The University of Western Ontario, Lawson is committed to furthering scientific knowledge to advance health care around the world. Its state-of-the-art, 6,000 sq. ft. Cyclotron & PET Radiochemistry Facility opened on March 31, 2010 and includes a GE PETtrace 880 cyclotron with proton and deuteron acceleration capability, class 100 shielded hot cells, and automated chemistry units for producing F-18 and C-11 radiopharmaceuticals - all to GMP specifications.

SOURCE: TRIUMF (Canada's National Laboratory of Particle and Nuclear Physics)

Media Contacts

Tim Meyer       Tel: 604.222.7674
Head, Strategic Planning & Communication   Cell: 604.235.1925
TRIUMF       E-mail: [email protected]

Modal title

Organization Profile

TRIUMF (Canada's National Laboratory of Particle and Nuclear Physics)

Contact Cision

  • 866-245-2317
    from 8 AM - 10 PM ET
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media

Products

  • Cision Communications Cloud®
  • Media Monitoring
  • Content Distribution
  • Multimedia Distribution
  • Measurement & Analytics
  • Investor Relations

About

  • About Cision Canada
  • About Cision
  • Media Partners
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Online Member Centre
  • Next Gen Communications Cloud
  • Cision Communications Cloud®
  • my CNW

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Centre
  • Next Gen Communications Cloud
  • Cision Communications Cloud
  • my CNW
877-269-7890
from 8 AM - 10 PM ET
  • Terms of Use
  • Information Security Policy
  • Site Map
  • Cookie Settings
  • Accessibility Statement
Copyright © 2025 CNW Group Ltd. All Rights Reserved. A Cision company.